Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-12-07

AUTHORS

Samuel J. P. Malkin, Monika Russel-Szymczyk, Girtel Liidemann, Vallo Volke, Barnaby Hunt

ABSTRACT

IntroductionOnce-weekly semaglutide is a novel glucagon-like peptide-1 (GLP-1) analogue for the treatment of type 2 diabetes that was associated with greater reductions in glycated hemoglobin (HbA1c) and body mass index (BMI) versus once-daily GLP-1 analogue liraglutide in a recent network meta-analysis (NMA). The aim of the present study was to assess the long-term cost-effectiveness of once-weekly semaglutide 1 mg versus liraglutide 1.2 mg in Estonia.MethodsOutcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model (version 9.0), with baseline cohort characteristics sourced from SUSTAIN 3 and changes in HbA1c, systolic blood pressure (SBP), and BMI associated with once-weekly semaglutide and liraglutide derived from the NMA. Patients were assumed to receive once-weekly semaglutide or liraglutide for 5 years before intensifying to basal insulin. Treatment effects were applied for the first 5 years, after which HbA1c increased to 7.0%, SBP followed a natural progression, and BMI reverted to baseline for the remainder of the analysis. Costs were expressed in euros (EUR) and estimated from a healthcare payer perspective. Utilities associated with diabetes and diabetes-related complications were taken from published sources.ResultsOnce-weekly semaglutide 1 mg was associated with improvements in quality-adjusted life expectancy of 0.13 quality-adjusted life years (QALYs) versus liraglutide 1.2 mg. Direct costs were EUR 67 higher with once-weekly semaglutide, due to the increased acquisition cost, but this was mostly offset by cost savings due to avoidance of diabetes-related complications. Once-weekly semaglutide 1 mg was therefore associated with an incremental cost-effectiveness ratio of EUR 523 per QALY gained versus liraglutide 1.2 mg, which falls well below a willingness-to-pay threshold of EUR 52,390 per QALY gained (three times the Estonian GDP per capita).ConclusionOnce-weekly semaglutide was considered highly cost-effective versus liraglutide 1.2 mg for the treatment of patients with type 2 diabetes in Estonia.FundingNovo Nordisk A/S.Plain Language SummaryPlain language summary available for this article. More... »

PAGES

159-176

References to SciGraph publications

  • 2018-04-19. A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1–2 Oral Anti-Diabetic Drugs in DIABETES THERAPY
  • 2013-06-03. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries in HEALTH AND QUALITY OF LIFE OUTCOMES
  • 2001-09. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes in DIABETOLOGIA
  • 2009-08-14. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial in DIABETOLOGIA
  • 2015-01-13. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes in DIABETOLOGIA
  • 2014-05-17. Diminishing marginal disutility of hypoglycaemic events: results from a time trade-off survey in five countries in QUALITY OF LIFE RESEARCH
  • 2007-07-19. Utilities and disutilities for type 2 diabetes treatment-related attributes in QUALITY OF LIFE RESEARCH
  • 2004-10-27. A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68) in DIABETOLOGIA
  • 2010-03-12. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes in THE EUROPEAN JOURNAL OF HEALTH ECONOMICS
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s13300-018-0542-x

    DOI

    http://dx.doi.org/10.1007/s13300-018-0542-x

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1110449103

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/30535837


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Ossian Health Economics and Communications, Basel, Switzerland", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Ossian Health Economics and Communications, Basel, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Malkin", 
            "givenName": "Samuel J. P.", 
            "id": "sg:person.012067446720.22", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012067446720.22"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Novo Nordisk Pharma Sp. z o.o, Warsaw, Poland", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Novo Nordisk Pharma Sp. z o.o, Warsaw, Poland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Russel-Szymczyk", 
            "givenName": "Monika", 
            "id": "sg:person.01340720514.56", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340720514.56"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Novo Nordisk A/S Eesti Filiaal, Tallinn, Estonia", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Novo Nordisk A/S Eesti Filiaal, Tallinn, Estonia"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Liidemann", 
            "givenName": "Girtel", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Tartu University Hospital, Tartu, Estonia", 
              "id": "http://www.grid.ac/institutes/grid.412269.a", 
              "name": [
                "Department of Physiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia", 
                "Tartu University Hospital, Tartu, Estonia"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Volke", 
            "givenName": "Vallo", 
            "id": "sg:person.01112043156.19", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01112043156.19"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Ossian Health Economics and Communications, Basel, Switzerland", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Ossian Health Economics and Communications, Basel, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hunt", 
            "givenName": "Barnaby", 
            "id": "sg:person.01346701147.33", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346701147.33"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/s10198-010-0224-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1029908098", 
              "https://doi.org/10.1007/s10198-010-0224-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s13300-018-0424-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1103465312", 
              "https://doi.org/10.1007/s13300-018-0424-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00125-004-1527-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1036304902", 
              "https://doi.org/10.1007/s00125-004-1527-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00125-009-1472-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1013300593", 
              "https://doi.org/10.1007/s00125-009-1472-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00125-014-3460-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1015538250", 
              "https://doi.org/10.1007/s00125-014-3460-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/pl00002934", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1048891551", 
              "https://doi.org/10.1007/pl00002934"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1477-7525-11-90", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1013049175", 
              "https://doi.org/10.1186/1477-7525-11-90"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s11136-007-9226-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1029076960", 
              "https://doi.org/10.1007/s11136-007-9226-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s11136-014-0712-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041603789", 
              "https://doi.org/10.1007/s11136-014-0712-x"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2018-12-07", 
        "datePublishedReg": "2018-12-07", 
        "description": "IntroductionOnce-weekly semaglutide is a novel glucagon-like peptide-1 (GLP-1) analogue for the treatment of type 2 diabetes that was associated with greater reductions in glycated hemoglobin (HbA1c) and body mass index (BMI) versus once-daily GLP-1 analogue liraglutide in a recent network meta-analysis (NMA). The aim of the present study was to assess the long-term cost-effectiveness of once-weekly semaglutide 1\u00a0mg versus liraglutide 1.2\u00a0mg in Estonia.MethodsOutcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model (version 9.0), with baseline cohort characteristics sourced from SUSTAIN 3 and changes in HbA1c, systolic blood pressure (SBP), and BMI associated with once-weekly semaglutide and liraglutide derived from the NMA. Patients were assumed to receive once-weekly semaglutide or liraglutide for 5\u00a0years before intensifying to basal insulin. Treatment effects were applied for the first 5\u00a0years, after which HbA1c increased to 7.0%, SBP followed a natural progression, and BMI reverted to baseline for the remainder of the analysis. Costs were expressed in euros (EUR) and estimated from a healthcare payer perspective. Utilities associated with diabetes and diabetes-related complications were taken from published sources.ResultsOnce-weekly semaglutide 1\u00a0mg was associated with improvements in quality-adjusted life expectancy of 0.13\u00a0quality-adjusted life years (QALYs) versus liraglutide 1.2\u00a0mg. Direct costs were EUR\u00a067 higher with once-weekly semaglutide, due to the increased acquisition cost, but this was mostly offset by cost savings due to avoidance of diabetes-related complications. Once-weekly semaglutide 1\u00a0mg was therefore associated with an incremental cost-effectiveness ratio of EUR\u00a0523 per QALY gained versus liraglutide 1.2\u00a0mg, which falls well below a willingness-to-pay threshold of EUR\u00a052,390 per QALY gained (three times the Estonian GDP per capita).ConclusionOnce-weekly semaglutide was considered highly cost-effective versus liraglutide 1.2\u00a0mg for the treatment of patients with type 2 diabetes in Estonia.FundingNovo Nordisk A/S.Plain Language SummaryPlain language summary available for this article.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s13300-018-0542-x", 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1044057", 
            "issn": [
              "1869-6953", 
              "1869-6961"
            ], 
            "name": "Diabetes Therapy", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "10"
          }
        ], 
        "keywords": [
          "body mass index", 
          "quality-adjusted life years", 
          "systolic blood pressure", 
          "weekly semaglutide 1", 
          "diabetes-related complications", 
          "liraglutide 1.2", 
          "type 2 diabetes", 
          "weekly semaglutide", 
          "novel glucagon-like peptide-1 (GLP-1) analogue", 
          "glucagon-like peptide-1 analog", 
          "long-term cost-effectiveness analysis", 
          "GLP-1 analogue liraglutide", 
          "incremental cost-effectiveness ratio", 
          "threshold of euro", 
          "Baseline cohort characteristics", 
          "peptide-1 analog", 
          "treatment of patients", 
          "healthcare payer perspective", 
          "quality-adjusted life expectancy", 
          "cost-effectiveness ratio", 
          "cost-effectiveness analysis", 
          "daily liraglutide", 
          "basal insulin", 
          "analogue liraglutide", 
          "blood pressure", 
          "mass index", 
          "IQVIA CORE", 
          "patient's lifetime", 
          "payer perspective", 
          "semaglutide", 
          "liraglutide", 
          "cohort characteristics", 
          "type 2", 
          "life years", 
          "diabetes", 
          "natural progression", 
          "direct costs", 
          "life expectancy", 
          "greater reduction", 
          "treatment effects", 
          "complications", 
          "patients", 
          "treatment", 
          "present study", 
          "acquisition costs", 
          "years", 
          "HbA1c", 
          "MethodsOutcomes", 
          "cost savings", 
          "insulin", 
          "baseline", 
          "progression", 
          "hemoglobin", 
          "NMA", 
          "Versus", 
          "expectancy", 
          "recent network", 
          "aim", 
          "index", 
          "remainder", 
          "euro", 
          "summary", 
          "study", 
          "reduction", 
          "effect", 
          "utility", 
          "analysis", 
          "improvement", 
          "avoidance", 
          "changes", 
          "pressure", 
          "threshold", 
          "analogues", 
          "willingness", 
          "ratio", 
          "s.", 
          "cost", 
          "characteristics", 
          "Estonia", 
          "article", 
          "Language Summary", 
          "model", 
          "perspective", 
          "source", 
          "savings", 
          "network", 
          "lifetime", 
          "core"
        ], 
        "name": "Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia", 
        "pagination": "159-176", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1110449103"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s13300-018-0542-x"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "30535837"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s13300-018-0542-x", 
          "https://app.dimensions.ai/details/publication/pub.1110449103"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-11-24T21:02", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_770.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s13300-018-0542-x"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-018-0542-x'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-018-0542-x'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-018-0542-x'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-018-0542-x'


     

    This table displays all metadata directly associated to this object as RDF triples.

    220 TRIPLES      21 PREDICATES      121 URIs      104 LITERALS      7 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s13300-018-0542-x schema:about anzsrc-for:11
    2 anzsrc-for:1103
    3 schema:author N4734e9c0b19b4eef8014f219a8dae73f
    4 schema:citation sg:pub.10.1007/pl00002934
    5 sg:pub.10.1007/s00125-004-1527-z
    6 sg:pub.10.1007/s00125-009-1472-y
    7 sg:pub.10.1007/s00125-014-3460-0
    8 sg:pub.10.1007/s10198-010-0224-8
    9 sg:pub.10.1007/s11136-007-9226-0
    10 sg:pub.10.1007/s11136-014-0712-x
    11 sg:pub.10.1007/s13300-018-0424-2
    12 sg:pub.10.1186/1477-7525-11-90
    13 schema:datePublished 2018-12-07
    14 schema:datePublishedReg 2018-12-07
    15 schema:description IntroductionOnce-weekly semaglutide is a novel glucagon-like peptide-1 (GLP-1) analogue for the treatment of type 2 diabetes that was associated with greater reductions in glycated hemoglobin (HbA1c) and body mass index (BMI) versus once-daily GLP-1 analogue liraglutide in a recent network meta-analysis (NMA). The aim of the present study was to assess the long-term cost-effectiveness of once-weekly semaglutide 1 mg versus liraglutide 1.2 mg in Estonia.MethodsOutcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model (version 9.0), with baseline cohort characteristics sourced from SUSTAIN 3 and changes in HbA1c, systolic blood pressure (SBP), and BMI associated with once-weekly semaglutide and liraglutide derived from the NMA. Patients were assumed to receive once-weekly semaglutide or liraglutide for 5 years before intensifying to basal insulin. Treatment effects were applied for the first 5 years, after which HbA1c increased to 7.0%, SBP followed a natural progression, and BMI reverted to baseline for the remainder of the analysis. Costs were expressed in euros (EUR) and estimated from a healthcare payer perspective. Utilities associated with diabetes and diabetes-related complications were taken from published sources.ResultsOnce-weekly semaglutide 1 mg was associated with improvements in quality-adjusted life expectancy of 0.13 quality-adjusted life years (QALYs) versus liraglutide 1.2 mg. Direct costs were EUR 67 higher with once-weekly semaglutide, due to the increased acquisition cost, but this was mostly offset by cost savings due to avoidance of diabetes-related complications. Once-weekly semaglutide 1 mg was therefore associated with an incremental cost-effectiveness ratio of EUR 523 per QALY gained versus liraglutide 1.2 mg, which falls well below a willingness-to-pay threshold of EUR 52,390 per QALY gained (three times the Estonian GDP per capita).ConclusionOnce-weekly semaglutide was considered highly cost-effective versus liraglutide 1.2 mg for the treatment of patients with type 2 diabetes in Estonia.FundingNovo Nordisk A/S.Plain Language SummaryPlain language summary available for this article.
    16 schema:genre article
    17 schema:isAccessibleForFree true
    18 schema:isPartOf Na8a4f59690a14058a8d7b69d7a087ee1
    19 Na96491045dbe45f08d56bc7622e1d311
    20 sg:journal.1044057
    21 schema:keywords Baseline cohort characteristics
    22 Estonia
    23 GLP-1 analogue liraglutide
    24 HbA1c
    25 IQVIA CORE
    26 Language Summary
    27 MethodsOutcomes
    28 NMA
    29 Versus
    30 acquisition costs
    31 aim
    32 analogue liraglutide
    33 analogues
    34 analysis
    35 article
    36 avoidance
    37 basal insulin
    38 baseline
    39 blood pressure
    40 body mass index
    41 changes
    42 characteristics
    43 cohort characteristics
    44 complications
    45 core
    46 cost
    47 cost savings
    48 cost-effectiveness analysis
    49 cost-effectiveness ratio
    50 daily liraglutide
    51 diabetes
    52 diabetes-related complications
    53 direct costs
    54 effect
    55 euro
    56 expectancy
    57 glucagon-like peptide-1 analog
    58 greater reduction
    59 healthcare payer perspective
    60 hemoglobin
    61 improvement
    62 incremental cost-effectiveness ratio
    63 index
    64 insulin
    65 life expectancy
    66 life years
    67 lifetime
    68 liraglutide
    69 liraglutide 1.2
    70 long-term cost-effectiveness analysis
    71 mass index
    72 model
    73 natural progression
    74 network
    75 novel glucagon-like peptide-1 (GLP-1) analogue
    76 patient's lifetime
    77 patients
    78 payer perspective
    79 peptide-1 analog
    80 perspective
    81 present study
    82 pressure
    83 progression
    84 quality-adjusted life expectancy
    85 quality-adjusted life years
    86 ratio
    87 recent network
    88 reduction
    89 remainder
    90 s.
    91 savings
    92 semaglutide
    93 source
    94 study
    95 summary
    96 systolic blood pressure
    97 threshold
    98 threshold of euro
    99 treatment
    100 treatment effects
    101 treatment of patients
    102 type 2
    103 type 2 diabetes
    104 utility
    105 weekly semaglutide
    106 weekly semaglutide 1
    107 willingness
    108 years
    109 schema:name Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia
    110 schema:pagination 159-176
    111 schema:productId N7bc985a9e85c44f580474f620b94c727
    112 N8566f5ced8bf41d7955379c166747f5e
    113 N915b92c1e27c442fa4f0ab14a16a393f
    114 schema:sameAs https://app.dimensions.ai/details/publication/pub.1110449103
    115 https://doi.org/10.1007/s13300-018-0542-x
    116 schema:sdDatePublished 2022-11-24T21:02
    117 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    118 schema:sdPublisher Nd82127b81f6948d185c2e994b6cbe1d4
    119 schema:url https://doi.org/10.1007/s13300-018-0542-x
    120 sgo:license sg:explorer/license/
    121 sgo:sdDataset articles
    122 rdf:type schema:ScholarlyArticle
    123 N4734e9c0b19b4eef8014f219a8dae73f rdf:first sg:person.012067446720.22
    124 rdf:rest Na18e88997dd2406c8f17cfd9a0f3802f
    125 N7bc985a9e85c44f580474f620b94c727 schema:name pubmed_id
    126 schema:value 30535837
    127 rdf:type schema:PropertyValue
    128 N8566f5ced8bf41d7955379c166747f5e schema:name doi
    129 schema:value 10.1007/s13300-018-0542-x
    130 rdf:type schema:PropertyValue
    131 N915b92c1e27c442fa4f0ab14a16a393f schema:name dimensions_id
    132 schema:value pub.1110449103
    133 rdf:type schema:PropertyValue
    134 Na18e88997dd2406c8f17cfd9a0f3802f rdf:first sg:person.01340720514.56
    135 rdf:rest Nda395df48b714da6ae1369bb5794f615
    136 Na390fbfd53464a0b90bcd94072eff1b2 rdf:first sg:person.01346701147.33
    137 rdf:rest rdf:nil
    138 Na8a4f59690a14058a8d7b69d7a087ee1 schema:volumeNumber 10
    139 rdf:type schema:PublicationVolume
    140 Na96491045dbe45f08d56bc7622e1d311 schema:issueNumber 1
    141 rdf:type schema:PublicationIssue
    142 Nd82127b81f6948d185c2e994b6cbe1d4 schema:name Springer Nature - SN SciGraph project
    143 rdf:type schema:Organization
    144 Nda395df48b714da6ae1369bb5794f615 rdf:first Nf00289beec264e859b2b7b99ee21e176
    145 rdf:rest Ndb6114da400c40b5b993e88fbbe40479
    146 Ndb6114da400c40b5b993e88fbbe40479 rdf:first sg:person.01112043156.19
    147 rdf:rest Na390fbfd53464a0b90bcd94072eff1b2
    148 Nf00289beec264e859b2b7b99ee21e176 schema:affiliation grid-institutes:None
    149 schema:familyName Liidemann
    150 schema:givenName Girtel
    151 rdf:type schema:Person
    152 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    153 schema:name Medical and Health Sciences
    154 rdf:type schema:DefinedTerm
    155 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    156 schema:name Clinical Sciences
    157 rdf:type schema:DefinedTerm
    158 sg:journal.1044057 schema:issn 1869-6953
    159 1869-6961
    160 schema:name Diabetes Therapy
    161 schema:publisher Springer Nature
    162 rdf:type schema:Periodical
    163 sg:person.01112043156.19 schema:affiliation grid-institutes:grid.412269.a
    164 schema:familyName Volke
    165 schema:givenName Vallo
    166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01112043156.19
    167 rdf:type schema:Person
    168 sg:person.012067446720.22 schema:affiliation grid-institutes:None
    169 schema:familyName Malkin
    170 schema:givenName Samuel J. P.
    171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012067446720.22
    172 rdf:type schema:Person
    173 sg:person.01340720514.56 schema:affiliation grid-institutes:None
    174 schema:familyName Russel-Szymczyk
    175 schema:givenName Monika
    176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340720514.56
    177 rdf:type schema:Person
    178 sg:person.01346701147.33 schema:affiliation grid-institutes:None
    179 schema:familyName Hunt
    180 schema:givenName Barnaby
    181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346701147.33
    182 rdf:type schema:Person
    183 sg:pub.10.1007/pl00002934 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048891551
    184 https://doi.org/10.1007/pl00002934
    185 rdf:type schema:CreativeWork
    186 sg:pub.10.1007/s00125-004-1527-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1036304902
    187 https://doi.org/10.1007/s00125-004-1527-z
    188 rdf:type schema:CreativeWork
    189 sg:pub.10.1007/s00125-009-1472-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1013300593
    190 https://doi.org/10.1007/s00125-009-1472-y
    191 rdf:type schema:CreativeWork
    192 sg:pub.10.1007/s00125-014-3460-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015538250
    193 https://doi.org/10.1007/s00125-014-3460-0
    194 rdf:type schema:CreativeWork
    195 sg:pub.10.1007/s10198-010-0224-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029908098
    196 https://doi.org/10.1007/s10198-010-0224-8
    197 rdf:type schema:CreativeWork
    198 sg:pub.10.1007/s11136-007-9226-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029076960
    199 https://doi.org/10.1007/s11136-007-9226-0
    200 rdf:type schema:CreativeWork
    201 sg:pub.10.1007/s11136-014-0712-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1041603789
    202 https://doi.org/10.1007/s11136-014-0712-x
    203 rdf:type schema:CreativeWork
    204 sg:pub.10.1007/s13300-018-0424-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103465312
    205 https://doi.org/10.1007/s13300-018-0424-2
    206 rdf:type schema:CreativeWork
    207 sg:pub.10.1186/1477-7525-11-90 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013049175
    208 https://doi.org/10.1186/1477-7525-11-90
    209 rdf:type schema:CreativeWork
    210 grid-institutes:None schema:alternateName Novo Nordisk A/S Eesti Filiaal, Tallinn, Estonia
    211 Novo Nordisk Pharma Sp. z o.o, Warsaw, Poland
    212 Ossian Health Economics and Communications, Basel, Switzerland
    213 schema:name Novo Nordisk A/S Eesti Filiaal, Tallinn, Estonia
    214 Novo Nordisk Pharma Sp. z o.o, Warsaw, Poland
    215 Ossian Health Economics and Communications, Basel, Switzerland
    216 rdf:type schema:Organization
    217 grid-institutes:grid.412269.a schema:alternateName Tartu University Hospital, Tartu, Estonia
    218 schema:name Department of Physiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia
    219 Tartu University Hospital, Tartu, Estonia
    220 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...